Amicus Therapeutics, Inc.

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh

Teva will have to wait more than a decade to launch its proposed generic version of Amicus Therapeutics’ ultra-rare genetic disorder treatment Galafold (migalastat) 123mg capsules, after reaching a se

The world of mid-cap biotech is no stranger to share price volatility, but a handful of companies have enjoyed the upside, emerging as rising stars this year thanks to eye-catching early results. A re

The US first-approver advantage over the European Union remains stark, with eight of ten novel agents first cleared by the US Food and Drug Administration, according to a Pink Sheet analysis of rece